Working… Menu

AZD9291 US Expanded Access Program

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02451852
Expanded Access Status : No longer available
First Posted : May 22, 2015
Last Update Posted : July 14, 2016
Information provided by (Responsible Party):

Brief Summary:
To provide access to AZD9291 for adult patients with advanced/metastatic, epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.

Condition or disease Intervention/treatment
EGFR T790M Mutation Positive NSCLC Drug: AZD9291

Detailed Description:
- This is a multi-center, AZD9291 expanded access protocol for the treatment of adult patients with advanced/metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) who have received prior EGFR TKI therapy and at least one additional line of therapy (≥ 3rd line). Local testing is accepted for confirmation of T790 mutation status. Eligible patients will be enrolled to receive AZD9291 (80mg orally, once daily) for as long as the access program remains open and they are continuing to show clinical benefit, as judged by the treating physician

Layout table for study information
Study Type : Expanded Access
Official Title: A Multi-center, AZD9291 Expanded Access Program for the Treatment of Patients With Advanced/Metastatic EGFR T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC) Who Have Received Prior EGFR TKI Therapy

Resource links provided by the National Library of Medicine

Drug Information available for: Osimertinib

Intervention Details:
  • Drug: AZD9291
    AZD9291 80mg tablet once daily, open label

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provision of signed and dated, written informed consent prior to any treatment protocol-specific procedures
  • Patients aged at least 18 years
  • Locally advanced or metastatic EGFRm NSCLC, not amenable to curative surgery or radiotherapy with confirmation of the presence of the T790M mutation
  • Two lines of prior therapy including at least one EGFR TKI
  • World Health Organization (WHO) performance status 0-2.
  • Females of child-bearing potential must use adequate contraceptive measures, not be breast-feeding and have negative pregnancy test prior to start of dosing.
  • Males patients should be willing to use barrier contraception.

Exclusion Criteria:

  • Previous treatment with AZD9291
  • Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of AZD9291) any treatment known to be potent inhibitors or inducers of CYP3A4
  • Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or significantly impaired bone marrow reserve or organ function, including hepatic and renal impairment, which in the clinician's opinion would significantly alter the risk/benefit balance, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
  • Patients with symptomatic CNS metastases who are neurologically unstable
  • Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
  • Any of the following cardiac criteria:

    1. Mean resting corrected QT interval (QTc using Fredericia's formula) > 470 msec
    2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)
    3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval
  • Any unresolved toxicity from prior therapy Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 at the time of starting treatment in the access program
  • History of hypersensitivity to AZD9291 (or drugs with a similar chemical structure or class to AZD9291) or any excipients of these agents
  • Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to access program entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02451852

Layout table for location information
United States, California
Research Site
Anaheim, California, United States
Research Site
Beverly Hills, California, United States
Research Site
Burbank, California, United States
Research Site
Santa Barbara, California, United States
Research Site
Santa Rosa, California, United States
United States, Connecticut
Research Site
Manchester, Connecticut, United States
United States, Florida
Research Site
Boca Raton, Florida, United States
Research Site
Fleming Island, Florida, United States
United States, Georgia
Research Site
Athens, Georgia, United States
United States, Hawaii
Research Site
Honolulu, Hawaii, United States
United States, Illinois
Research Site
Chicago, Illinois, United States
United States, Maryland
Research Site
Chevy Chase, Maryland, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
United States, Michigan
Research Site
Detroit, Michigan, United States
Research Site
Lansing, Michigan, United States
United States, Minnesota
Research Site
Rochester, Minnesota, United States
United States, Nebraska
Research Site
Lincoln, Nebraska, United States
United States, New Jersey
Research Site
Paramus, New Jersey, United States
United States, New York
Research Site
Buffalo, New York, United States
Research Site
Fresh Meadows, New York, United States
Research Site
Mineola, New York, United States
Research Site
New York, New York, United States
United States, North Carolina
Research Site
Charlotte, North Carolina, United States
Research Site
Winston Salem, North Carolina, United States
United States, Ohio
Research Site
Columbus, Ohio, United States
United States, South Dakota
Research Site
Sioux Falls, South Dakota, United States
United States, Texas
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
United States, Virginia
Research Site
Fairfax, Virginia, United States
Research Site
Warrenton, Virginia, United States
United States, Washington
Research Site
Lacey, Washington, United States
Research Site
Seattle, Washington, United States
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: AstraZeneca Identifier: NCT02451852    
Other Study ID Numbers: D5160C00021
First Posted: May 22, 2015    Key Record Dates
Last Update Posted: July 14, 2016
Last Verified: July 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action